Clinical Implications of Targeting XPO1-Mediated Nuclear Export in Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia - United States
doi 10.1016/j.clml.2018.03.003
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Clinical Implications of Cytogenetic Heterogeneity in Multiple Myeloma Patients With TP53 Deletion

Modern Pathology
Forensic MedicinePathology
2017English

Targeting the Pim Kinases in Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2015English

Nuclear Export of the Yeast Hexokinase 2 Protein Requires the Xpo1 (Crm1)-Dependent Pathway

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2009English

Clinical Implications of C-Maf Expression in Plasma Cells From Patients With Multiple Myeloma

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2017English

Hitting a Moving Target: Inhibition of the Nuclear Export Receptor XPO1/CRM1 as a Therapeutic Approach in Cancer

2018English

The Therapeutic Potential of Cell Cycle Targeting in Multiple Myeloma

Oncotarget
Oncology
2017English

Microenvironmental Influence on Pre-Clinical Activity of Polo-Like Kinase Inhibition in Multiple Myeloma: Implications for Clinical Translation

PLoS ONE
Multidisciplinary
2011English

Targeting the Phosphatidylinositol 3-Kinase Pathway in Multiple Myeloma

Clinical Cancer Research
Cancer ResearchOncology
2007English

HDAC3 Regulates DNMT1 Expression in Multiple Myeloma: Therapeutic Implications

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy